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symptoms and its association with mood and
anxiety disorders and psychological
symptomology: a population-based study in
women
Livia Sanna1,2, Amanda L Stuart2, Michael Berk2,3,4, Julie A Pasco2,5,6,7, Paolo Girardi1 and Lana J Williams2,3*Abstract
Background: Psychopathology seems to play a role in reflux pathogenesis and vice versa, yet few population-
based studies have systematically investigated the association between gastro-oesophageal reflux disease (GORD)
and psychopathology. We thus aimed to investigate the relationship between GORD-related symptoms and
psychological symptomatology, as well as clinically diagnosed mood and anxiety disorders in a randomly selected,
population-based sample of adult women.
Methods: This study examined data collected from 1084 women aged 20-93 yr participating in the Geelong
Osteoporosis Study. Mood and anxiety disorders were identified using the Structured Clinical Interview for DSM-IV-
TR Research Version, Non-patient edition (SCID-I/NP), and psychological symptomatology was assessed using the
General Health Questionnaire (GHQ-12). GORD-related symptoms were self-reported and confirmed by medication
use where possible and lifestyle factors were documented.
Results: Current psychological symptomatology and mood disorder were associated with increased odds of
concurrent GORD-related symptoms (adjusted OR 2.1, 95% CI 1.3-3.5, and OR 3.0, 95% CI 1.7-5.6, respectively). Current
anxiety disorder also tended to be associated with increased odds of current GORD-related symptoms (p = 0.1).
Lifetime mood disorder was associated with a 1.6-fold increased odds of lifetime GORD-related symptoms (adjusted OR
1.6, 95% CI 1.1-2.4) and lifetime anxiety disorder was associated with a 4-fold increased odds of lifetime GORD-related
symptoms in obese but not non-obese participants (obese, age-adjusted OR 4.0, 95% CI 1.8-9.0).
Conclusions: These results indicate that psychological symptomatology, mood and anxiety disorders are positively
associated with GORD-related symptoms. Acknowledging this common comorbidity may facilitate recognition and
treatment, and opens new questions as to the pathways and mechanisms of the association.
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Researchers have repeatedly hypothesized that psycho-
pathology plays a role in reflux pathogenesis and vice
versa [1-4]. Gastro-oesophageal reflux disease (GORD) is
a common condition due to stomach content flowing
back through the lower oesophageal sphincter (LOS),
causing bothersome symptomatology characterized by
acid regurgitation and heartburn [5]. Prevalence figures
vary from 20% of the general population in the United
States and the United Kingdom to 5% in China, with
Australian studies reporting a prevalence of 9.2% [6,7].
While there is an extensive evidence base suggesting
an association between irritable bowel syndrome and
psychiatric disorders [8], associations with GORD are
relatively poorly researched. GORD and mental well-
being have been examined in both gastrointestinal and
psychiatric-based clinical care settings with reports of in-
creased likelihood of GORD amongst depressed individ-
uals [9,10] and increased risk of mental illness including
depression and anxiety [11], neuroticism [12] and psy-
chological distress [2,3,13] amongst GORD sufferers.
Furthermore, frequency and duration of GORD symp-
toms [2] and a poorer response to treatment including
surgical intervention [14] and proton pump inhibitor
therapy [4,5], have also been linked to mental well-
being. On the other hand, Kamolz and colleagues dem-
onstrated improvements in mental health related quality
of life following surgery for GORD [15].
Few population-based studies have investigated the as-
sociation between GORD-related symptoms and psycho-
pathology [16]. Those that have, report increased odds
of reflux in people suffering anxiety and depression, al-
though most utilising self-report symptom scales
[1,17,18] and one study using data from medical records
[10]. We have previously described increased odds of
GORD-related symptoms in men with mood and anxiety
disorders in the Geelong Osteoporosis Study (GOS) male
cohort, using the Structured Clinical Interview for DSM-
IV-TR Research Version, Non-patient edition (SCID-I/NP)
[19], thus providing a rationale for this study. Encouraged
by the need for population-based evidence, we aimed to in-
vestigate the relationship between GORD-related symp-
toms and psychological symptomatology, as well as
clinically diagnosed mood and anxiety disorders in a ran-
domly selected, population-based sample of adult women.
Methods
Participants
The Geelong Osteoporosis Study (GOS) is an age-
stratified random population-based sample of women
recruited from the Commonwealth of Australia electoral
rolls [20]. Participants were recruited from the Barwon
Statistical Division between 1994 and 1997, with an add-
itional sample of 20–29 year olds recruited between2004 and 2008, allowing for continuing investigation of
the full adult age range. From a pool of 1127 women who
participated in the GOS 10 year follow-up assessment, 32
who did not undergo the psychiatric assessment and 11
who did complete the medical history section were ex-
cluded from the current analyses, resulting in a final sam-
ple of 1,084 women aged 20-93 yr. Written informed
consent was obtained from all participants and the study
was approved by the Barwon Health Human Research
Ethics Committee.
Assessments
Data from the Structured Clinical Interview for DSM-
IV-TR Research Version, Non-patient edition (SCID-I/
NP) [21] was used to determine the age of onset of
mood and anxiety disorders. All psychiatric interviews
were conducted by trained personnel with qualifications
in psychology. Major depressive disorder, bipolar dis-
order (types I and II), dysthymia, minor depression,
mood disorder due to medical condition and substance
induced mood disorder were collectively termed mood
disorder. Anxiety disorder was defined as the presence
of panic disorder, agoraphobia, social phobia, specific
phobia, obsessive compulsive disorder, generalised anx-
iety disorder, anxiety disorder due to a medical condi-
tion, substance-induced anxiety disorder or anxiety
disorder not otherwise specified.
Psychological symptomatology was assessed using the
General Health Questionnaire (GHQ-12) [22], a vali-
dated screening tool designed to detect non-psychotic
psychiatric disorders in community settings, based on
assessment of current state. Binary scoring was used for
the 12 items, yielding total scores ranging from 0 to 12,
and a cut-off of >3 was applied to define caseness indica-
tive of mental health dysfunction [22,23].
Current medication use was documented. The presence
of GORD was self-reported and/or identified by use of
medication taken daily for hyperacidity, reflux or ulcers.
From a list of common medical conditions, participants
were asked, at interview, if they had ever experienced
GORD or GORD-related symptoms (lifetime yes/no) and
whether the condition had been present during the previ-
ous 12 months (current yes/no). Height was measured to
the nearest 0.1 cm and body weight to the nearest 0.1 kg.
Body mass index (BMI) was calculated as weight/height2
(kg/m2) [24]. Alcohol consumption (average grams con-
sumed daily over a 12 month period) was estimated using
a validated food frequency questionnaire [25]. Women
were classed as active if they participated in light to vigor-
ous activity on a regular basis. Tobacco smoking was clas-
sified as current or not. Socio-economic status (SES) was
determined using Socio-Economic Index For Areas
(SEIFA) scores based on the 2006 Australian Bureau of
Statistics Census data [26]. These values were used to
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advantage (IRSAD), which accounts for high and low in-
come, educational attainment, type of occupation, and
other measures of wealth (such as owning a car, or number
of bedrooms in a dwelling) and then divided into quintiles.
Statistical analysis
Statistical analyses were performed using Minitab (ver-
sion 16; Minitab, State College, PA). Values of p < 0.05
were accepted as significant. Differences in characteris-
tics between the groups were compared using chi-square
analyses and Mann–Whitney. Binary logistic regression
techniques were used to evaluate the relationship be-
tween current GORD-related symptoms and current
mood/anxiety disorders and psychological symptomatol-
ogy, and lifetime GORD-related symptoms and lifetime
mood/anxiety disorders. Models were adjusted for age,
alcohol consumption, BMI, SES, physical activity and
smoking status where appropriate and interactions be-
tween exposure variables were examined.
Results
Characteristics of the whole group (n = 1084) are shown
in Table 1. Of this group, 311 women (28.7%) had a life-
time history of mood disorder [major depressive disorder -
244 (78.5%), dysthymia - 19 (6.1%), minor depression - 31
(10.1%) and bipolar disorder - 23 (7.4%)] and 91 were
identified with current mood disorder [major depressiveTable 1 Characteristics for the whole group and women with
All Current GOR
Yes
n = 1084 n = 114
Age at interview (yr) 50.7(34.3, 65.9) 68.6 (58.4, 77.4)
BMI (kg/m2)* 26.3 (23.4, 55.0) 28.6 (25.0, 33.9)
Alcohol consumption (g/day)* 2.9 (0.3, 12.0) 0.8 (0.1, 11.0)
Smokers (current)* 153 (14.1%) 12 (10.5%)
Physically active* 840 (77.6%) 77 (67.5%)
Socio-economic status
Quintile 1 (most disadvantaged) 167 (15.4%) 21 (18.4%)
Quintile 2 232 (21.4%) 25 (21.9%)
Quintile 3 253 (23.3%) 28 (24.6%)
Quintile 4 211 (19.5%) 18 (15.6%)
Quintile 5 221 (20.4%) 22 (19.3%)
Mood disorder (current) 114 (10.6%) 18 (15.8%)
Anxiety disorder (current) 83 (7.7%) 11 (9.7%)
Current symptomatology (GHQ >3)* 161 (15.2%) 27 (25%)
Mood disorder (lifetime) 311 (28.7%) -
Anxiety disorder (lifetime) 144 (13.3%) -
*Missing values: BMI n = 29, alcohol consumption n = 33, physically active n = 2, sm
Values are given as median (IQR) or n (%).disorder - 48 (52.7%), dysthymia - 19 (20.8%), minor de-
pression - 13 (14.3%) and bipolar disorder - 14 (15.4%)]. A
total of 144 participants (13.3%) had a lifetime history of
anxiety disorder [generalised anxiety disorder – 10 (6.9%),
panic disorder - 59 (41.0%), agoraphobia – 8 (5.6%), social
phobia - 23 (16.0%), specific phobia - 36 (25.0%), obsessive
compulsive disorder 14 (9.7%), anxiety due to a general
medical condition - 2 (1.4%), substance-induced anxiety
disorder - 3 (2.1%) and anxiety disorder not otherwise spe-
cified - 17 (11.8%)] and 83 were identified with current
anxiety [generalised anxiety disorder – 10 (12.0%), panic
disorder - 14 (16.9%), agoraphobia – 6 (7.2%), social pho-
bia - 10 (12.0%), specific phobia - 32 (38.6%), obsessive
compulsive disorder 6 (7.2%), anxiety due to a general
medical condition - 1 (1.2%), substance-induced anxiety
disorder - 2 (2.4%) and anxiety disorder not otherwise spe-
cified - 12 (14.5%)].
Women with current GORD-related symptoms were
older, had a higher BMI, were less likely to be physically
active and were more likely to report psychological symp-
tomatology and have a current mood disorder; otherwise
the groups were similar (Table 1). Age- (model I) and age-
and BMI- adjusted (model II) odds ratios for women with
current GORD-related symptoms and mood/anxiety dis-
orders/symptomatology is shown in Table 2. Those with
current psychological symptomatology had increased odds
of concurrent GORD-related symptoms (adjusted OR 2.1,
95% CI 1.3-3.5, p = 0.005). Current mood disorders wereor without current and lifetime GORD
D-related symptoms* Lifetime GORD-related symptoms
No P value Yes No P value
n = 958 n = 151 n = 933
48.1 (32.1, 63.7) <0.001 66.1 (56.6,77.3) 47.8 (31.5, 63.2) <0.001
26.0 (23.2, 30.5) <0.001 28.3 (24.5, 33.6) 26.0 (23.3, 30.5) <0.001
3.1 (0.4, 12.2) 0.18 1.5 (0.0, 9.9) 3.2 (0.4, 12.4) 0.2
139 (14.5%) 0.25 16 (10.6%) 137 (14.7%) 0.18
758 (79.3%) 0.004 98 (64.9%) 742 (79.7%) <0.001
145 (15.1%) 0.79 27 (17.9%) 140 (15.0%) 0.85
206 (21.5%) 32 (21.2%) 200 (21.4%)
221 (23.1%) 37 (24.5%) 216 (23.2%)
188 (19.6%) 26 (17.2%) 185 (19.8%)
198 (20.7%) 29 (19.2%) 120 (20.6%)
72 (7.5%) 0.003 - - -
70 (7.3%) 0.37 - - -
129 (13.8%) 0.002 - - -
- - 47 (31.1%) 264 (28.3%) 0.48
- - 26 (17.2%) 118 (12.7%) 0.13
okers n = 1, current GORD n = 12, GHQ n = 27.
Table 2 Age-adjusted (model I) and age- and BMI- adjusted (model II) odds ratios for GORD in women with mood and
anxiety disorders and symptomatology
Model GORD-related symptoms - current
Odds ratio 95% CI P value
Symptomatology (current) I 2.2 (1.3 – 3.6) 0.003
II 2.1 (1.3 – 3.5) 0.005
Mood disorder (current) I 3.1 (1.7 – 5.6) <0.001
II 3.0 (1.7 – 5.6) <0.001
Anxiety disorder (current) I 1.8 (0.9 – 3.7) 0.10
II 1.8 (0.9 – 3.8) 0.10
Model GORD-related symptoms - lifetime
Odds ratio 95% CI P value
Mood disorder (lifetime) I 1.6 (1.1 – 2.5) 0.02
II 1.6 (1.1 – 2.4) 0.02
Anxiety disorder (lifetime) I- BMI <30 kg/m2 1.2 (0.6 – 2.4) 0.64
I- BMI >30 kg/m2 4.0 (1.8 – 9.0) 0.001
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related symptoms (adjusted OR 3.0, 95% CI 1.7-5.6, p <
0.001) and current anxiety disorder tended to be associ-
ated (adjusted OR 1.8, 95% CI 0.9-3.8, p = 0.10).
Those with a past history of GORD-related symptoms
were older, had a higher BMI, consumed less alcohol
and were less likely to be physically active than those
with no past history; otherwise the groups were similar
(Table 1). A lifetime history of mood disorders was asso-
ciated with a 1.6-fold increased odds of lifetime GORD-
related symptoms (adjusted OR 1.6, 95% CI 1.1-2.4, p =
0.03; Table 2). BMI was an effect modifier in the rela-
tionship between lifetime anxiety disorders and lifetime
GORD-related symptoms. Among obese women, lifetime
anxiety disorders were associated with a 4-fold increased
odds of lifetime GORD-related symptoms (age-adjusted
OR 4.0, 95% CI 1.8-9.0, p = 0.001). There was no associ-
ation between lifetime anxiety disorders and GORD-
related symptoms in non-obese women.
Discussion
This cross-sectional, population-based study showed a
strong association between psychological symptoms,
mood disorders and GORD-related symptoms in adult
women. The relationship between anxiety disorders and
GORD-related symptoms was not as consistent; a positive
trend was observed when comparing current anxiety dis-
orders and current GORD-related symptoms, however an
association between lifetime anxiety and GORD-related
symptoms was only evident among obese women.
Our findings are consistent with previously reported
community-based studies demonstrating a relationship
between GORD and psychological symptomatology and
mood/anxiety disorders [1,10,17,18]. In a Norwegian study(HUNT 2) of over 40,500 participants, those diagnosed
with reflux, defined by the presence of either severe symp-
toms of recurrent heartburn or acid regurgitation, showed
an increased likelihood of anxiety and depressive symp-
toms, as measured by the Hospital Anxiety and Depres-
sion Scale, compare to those without reflux [1]. Similarly,
another large-scale study [10] demonstrated a 72% in-
crease odds of GORD amongst those with depression in a
sample of over 40,000 individuals.
Among women with a lifetime history of anxiety dis-
order in our sample, only participants affected by obesity
were at increased risk of GORD-related symptoms. Find-
ings from Wiklund et al. [4] may help explain these re-
sults; BMI was shown to be associated with endoscopy-
negative reflux and patients affected by this type of re-
flux (functional heartburn) were more likely to have anx-
iety than those with endoscopy-positive acid reflux-
symptoms [5]. Thus our positive association between
anxiety and self-reported GORD-related symptoms in
participants with obesity may be due to them suffering
from functional heartburn, rather than GORD. The self-
reported diagnosis of GORD-related symptoms in our
sample does not allow clarification of this issue.
There are many possible explanations for the association
between psychopathology and GORD-related symptoms.
As suggested by Kamolz and Velonovich [16], the relation-
ship may be attributed to changes in oesophageal motility
and LOS function in response to stressors. In addition, vis-
ceral hypersensitivity, which would also explain the fre-
quent overlap between heartburn and irritable bowel
syndrome [27] may be caused by psychological factors in-
fluencing stimuli processing in the central nervous system
(CNS) [28]. Although little is known about the morpho-
logical organization of serotonergic neurons in the
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dicated that serotonin, the main target of both depression
and anxiety treatment, plays a role in oesophageal motility
[29,30], leading to neurohormonal interaction between the
CNS and the gastrointestinal system. On the other hand,
it is plausible that the presence of GORD-related symp-
toms can evoke feelings of depression or anxiety [16] or
that there are a subset of patients with co-occurring vul-
nerability to both mood/anxiety and reflux symptoms [3].
Lastly, there is no evidence, endoscopic or otherwise, that
identifies which factors of reflux are significantly related to
mental illness [2]. Therefore, future research should focus
on factors that mediate the relationship between psycho-
logical conditions and GORD, helping to pinpoint the
mechanism of action.
The comorbidity between psychological illness and
GORD has been shown to be clinically relevant, in that
the response to GORD treatment, both pharmacological
[5] and surgical [14], is lower amongst patients with psy-
chopathology, and certain antidepressants, especially tri-
cyclics, appear to aggravate GORD symptoms [10]. On
the other hand, studies have shown the efficacy of medi-
cations used to treat depression and anxiety, such as
trazodone [31] and citalopram [32], in improving
oesophageal symptoms. Thus, recognising the common
comorbidity amongst GORD and mood/anxiety disor-
ders may facilitate recognition, and aid treatment
choices. Furthermore, Nunez-Rodriguez [2] reported
that GORD was associated with other psychological
symptom patterns according to the Symptom CheckList-
90-R, suggesting the relationship between psychological
factors and reflux may extend beyond mood and anxiety
disorders.
Methodological limitations of the current study in-
clude the cross-sectional design, which precludes tem-
poral and causal speculation, self-reported GORD
diagnosis and the lack of severity evaluation of GORD-
related symptoms. Current diagnostic criteria for heart-
burn, based on endoscopic and pH-metric findings,
symptomatology and response to proton pump inhibitor
therapy, distinguish between erosive reflux disease, non-
erosive reflux disease and functional heartburn. Despite
this differentiation, Lee and colleagues [5] found depres-
sion not to differentiate in prevalence among the three
groups, whilst anxiety tended to be more prevalent in
the functional heartburn group. Furthermore, the
confounding role of somatisation, frequently associated
to depression and anxiety, and previously shown to be
related to heartburn symptomatology [2] was not exam-
ined. It is also possible that GORD-related symptoms ex-
perienced during pregnancy may have been included in
the lifetime history. However, as participants were not
assessed during pregnancy, it is unlikely that current
GORD-symptoms were pregnancy-related. Strengths ofthe current study include the population-based design
and combination of the two types of psychological as-
sessment; a reference standardized semi-structured diag-
nostic assessment (SCID-I/NP) and a self-report
questionnaire (GHQ-12). Most of the literature is based
only on self-report questionnaire [4,16], with findings
being extrapolated to reflect psychiatric diagnoses,
whereas we were able to investigate sub-threshold psy-
chopathology as well as diagnosed psychiatric disorders.
Conclusions
These results provide population-based evidence that
psychological symptomatology, mood and anxiety disor-
ders are positively associated with GORD-related symp-
toms. Further research dissecting the pathways and
mechanisms of this association is warranted. In the
meantime, taking a holistic approach to treatment of
these conditions is likely to improve symptoms, treat-
ment choices and prove cost-effective.
Abbreviations
BMI: Body mass index; CNS: Central nervous system; CI: Confidence Intervals;
GORD: Gastro oesophageal reflux disease; GOS: Geelong Osteoporosis Study;
GHQ-12: General Health Questionnaire; IRSAD: Index of relative
socioeconomic advantage/disadvantage; IQR: Interquartile range; LOS: Lower
oesophageal sphincter; OR: Odds ratio; SEIFA: Socio-economic index for
areas; SES: Socio-economic status; SCID-I/NP: Structured clinical interview for
DSM-IV-TR research version, non-patient edition; DSM-IV-TR: Diagnostic and
Statistical Manual of Mental Disorders, 4th edition, text revision.
Competing interests
Livia Sanna, Amanda L Stuart and Mark A Kotowicz have no conflicts of
interest, including specific financial interests and relationships and affiliations
relevant to the subject matter or materials discussed in the manuscript.
Paolo Girardi has in the past three years received research support from Lilly
and Janssen, participated in advisory boards for Lilly, Organon, Pfizer, and
Schering, and received honoraria from Lilly and Organon.
Julie A Pasco has received speaker fees from Amgen, Eli Lilly and Sanofi-
Aventis and funding from the Geelong Region Medical Research Foundation,
Barwon Health, Perpetual Trustees, the Dairy Research and Development
Corporation, The University of Melbourne, the Ronald Geoffrey Arnott
Foundation, ANZ Charitable Trust, the American Society for Bone and
Mineral Research, Amgen (Europe) GmBH and the NHMRC.
Michael Berk has received Grant/Research Support from the NIH, Simons
Foundation, CRC for Mental Health, Stanley Medical Research Institute, MBF,
NHMRC, Beyond Blue, Geelong Medical Research Foundation, Bristol Myers
Squibb, Eli Lilly, Glaxo SmithKline, Organon, Novartis, Mayne Pharma, Servier
and Astra Zeneca. He has been a paid consultant for Astra Zeneca, Bristol
Myers Squibb, Eli Lilly, Glaxo SmithKline, Janssen Cilag, Lundbeck and Pfizer
and a paid speaker for Astra Zeneca, Bristol Myers Squibb, Eli Lilly, Glaxo
SmithKline, Janssen Cilag, Lundbeck, Organon, Pfizer, Sanofi Synthelabo,
Solvay and Wyeth.
Lana J Williams has received Grant/Research support from Eli Lilly, Pfizer, The
University of Melbourne, Deakin University and the NHMRC.
Authors’ contributions
LS and ALS took part in the conception and design of the study, acquisition
of the data, data cleaning and statistical analysis, interpretation of the
analysis and took primary responsibility for writing the manuscript. MB, JAP
and MAK took part in the conception and design of the study, interpretation
of the analysis and critically revised the manuscript. PG took part in the
interpretation of data and critically revised the manuscript. LJW took part in
the conception and design of the study, interpretation of the analysis,
critically revised and supervised the writing of the manuscript. All authors
read and approved the final manuscript.
Sanna et al. BMC Psychiatry 2013, 13:194 Page 6 of 6
http://www.biomedcentral.com/1471-244X/13/194Acknowledgments
The study was funded by the National Health and Medical Research Council
(NHMRC) of Australia. The funding providers played no role in the design or
conduct of the study; collection, management, analysis, and interpretation of
the data; or in preparation, review, or approval of the manuscript.
The authors wish to acknowledge the women who participated in the study.
Author details
1Unit of Psychiatry, Neurosciences, Mental Health and Sensory Organs
Department (NeSMOS), Faculty of Medicine and Psychology, Sant’Andrea
Hospital, Sapienza University of Rome, Rome, Italy. 2IMPACT Strategic
Research Centre, School of Medicine, Deakin University, P.O. Box 281,
Geelong 3220, Australia. 3Department of Psychiatry, The University of
Melbourne, Parkville, Australia. 4Orygen Youth Health Research Centre,
Parkville, Australia. 5Florey Institute for Neuroscience and Mental Health,
The University of Melbourne, Parkville, Australia. 6NorthWest Academic
Centre, Department of Medicine, The University of Melbourne, Western
Health, St Albans, Australia. 7Department of Medicine, Barwon Health,
Geelong, Australia.
Received: 3 June 2013 Accepted: 5 June 2013
Published: 24 July 2013
References
1. Jansson C, Nordenstedt H, Wallander MA, Johansson S, Johnsen R, Hveem K,
Lagergren J: Severe gastro-oesophageal reflux symptoms in relation to
anxiety, depression and coping in a population-based study. Aliment
Pharmacol Ther 2007, 26:683–691.
2. Nunez-Rodriguez MH, Miranda Sivelo A: Psychological factors in
gastroesophageal reflux disease measured by scl-90-R questionnaire. Dig
Dis Sci 2008, 53:3071–3075.
3. Baker LH, Lieberman D, Oehlke M: Psychological distress in patients with
gastroesophageal reflux disease. Am J Gastroenterol 1995, 90:1797–1803.
4. Wiklund I, Carlsson R, Carlsson J, Glise H: Psychological factors as a
predictor of treatment response in patients with heartburn: a pooled
analysis of clinical trials. Scand J Gastroenterol 2006, 41:288–293.
5. Lee KJ, Kwon HC, Cheong JY, Cho SW: Demographic, clinical, and
psychological characteristics of the heartburn groups classified using the
Rome III criteria and factors associated with the responsiveness to
proton pump inhibitors in the gastroesophageal reflux disease group.
Digestion 2009, 79:131–136.
6. Dent J, El-Serag HB, Wallander MA, Johansson S: Epidemiology of gastro-
oesophageal reflux disease: a systematic review. Gut 2005, 54:710–717.
7. Knox SA, Harrison CM, Britt HC, Henderson JV: Estimating prevalence of
common chronic morbidities in Australia. Med J Aust 2008, 189:66–70.
8. Mykletun A, Jacka F, Williams L, Pasco J, Henry M, Nicholson GC, Kotowicz
MA, Berk M: Prevalence of mood and anxiety disorder in self reported
irritable bowel syndrome (IBS). An epidemiological population based
study of women. BMC Gastroenterol 2010, 10:88.
9. Avidan B, Sonnenberg A, Giblovich H, Sontag SJ: Reflux symptoms are
associated with psychiatric disease. Aliment Pharmacol Ther 2001,
15:1907–1912.
10. Martin-Merino E, Ruigomez A, Garcia Rodriguez LA, Wallander MA,
Johansson S: Depression and treatment with antidepressants are
associated with the development of gastro-oesophageal reflux disease.
Aliment Pharmacol Ther 2010, 31:1132–1140.
11. Hartono JL, Mahadeva S, Goh KL: Anxiety and depression in various
functional gastrointestinal disorders: do differences exist? J Dig Dis 2012,
13:252–257.
12. Lee YC, Wang HP, Chiu HM, Liao SC, Huang SP, Lai YP, Wu MS, Chen MF,
Lin JT: Comparative analysis between psychological and endoscopic
profiles in patients with gastroesophageal reflux disease: a prospective
study based on screening endoscopy. J Gastroenterol Hepatol 2006,
21:798–804.
13. Stanghellini V: Relationship between upper gastrointestinal symptoms
and lifestyle, psychosocial factors and comorbidity in the general
population: results from the Domestic/International Gastroenterology
Surveillance Study (DIGEST). Scand J Gastroenterol Suppl 1999, 231:29–37.
14. Velanovich V, Karmy-Jones R: Psychiatric disorders affect outcomes of
antireflux operations for gastroesophageal reflux disease. Surg Endosc
2001, 15:171–175.15. Kamolz T, Granderath PA, Bammer T, Pasiut M, Wykypiel H Jr, Herrmann R,
Pointner R: Mid- and long-term quality of life assessments after
laparoscopic fundoplication and refundoplication: a single unit review of
more than 500 antireflux procedures. Dig Liver Dis 2002, 34:470–476.
16. Kamolz T, Velanovich V: Psychological and emotional aspects of
gastroesophageal reflux disease. Dis Esophagus 2002, 15:199–203.
17. Lee SY, Lee KJ, Kim SJ, Cho SW: Prevalence and risk factors for overlaps
between gastroesophageal reflux disease, dyspepsia, and irritable bowel
syndrome: a population-based study. Digestion 2009, 79:196–201.
18. Lopez-Colombo A, Morgan D, Bravo-Gonzalez D, Montiel-Jarquin A,
Mendez-Martinez S, Schmulson M: The epidemiology of functional
gastrointestinal disorders in Mexico: a population-based study.
Gastroenterol Res Pract 2012, 2012:606174.
19. Sanna L, Stuart AL, Pasco JA, Kotowicz MA, Berk M, Girardi P, Brennan SL,
Williams LJ: Physical comorbidities in men with mood and anxiety
disorders: a population-based study. BMC Medicine 2013, 11:110.
20. Pasco JA, Nicholson GC, Kotowicz MA: Cohort profile: Geelong
osteoporosis study. Int J Epidemiol 2012, 41:1565–1575.
21. First M, Spitzer R, Gibbon M, Williams J: Structured clinical interview for DSM-
IVTR axis I disorders, research version, non-patient edition (SCID-I/NP). New
York: Biometrics Research, New York State Psychiatric Institute; 2002.
22. Goldberg DP: Manual of the general health questionnaire. Windsor: Nfer-
Nelson; 1978.
23. Goldberg DP, Gater R, Sartorius N, Ustun TB, Piccinelli M, Gureje O, Rutter C:
The validity of two versions of the GHQ in the WHO study of mental
illness in general health care. Psychol Med 1997, 27:191–197.
24. Pasco JA, Nicholson GC, Brennan SL, Kotowicz MA: Prevalence of obesity
and the relationship between the body mass index and body fat: cross-
sectional, population-based data. PLoS One 2012, 7:e29580.
25. Giles C, Ireland P: Dietary questionnaire for epidemiological studies (version 2).
Melbourne: The Cancer Council Victoria; 1996.
26. ABS ABoS: Socio-economic indixes for areas (SEIFA) - technical paper. In
Australian bureau of statistics. Edited by Statistics ABo 2006.
27. Dickman R, Feroze H, Fass R: Gastroesophageal reflux disease and irritable
bowel syndrome: a common overlap syndrome. Curr Gastroenterol Rep
2006, 8:261–265.
28. Geeraerts B, Vandenberghe J, Van Oudenhove L, Gregory LJ, Aziz Q, Dupont
P, Demyttenaere K, Janssens J, Tack J: Influence of experimentally induced
anxiety on gastric sensorimotor function in humans. Gastroenterology
2005, 129:1437–1444.
29. Pehlivanov N, Sarosiek I, Whitman R, Olyaee M, McCallum R: Effect of
cisapride on nocturnal transient lower oesophageal sphincter relaxations
and nocturnal gastro-oesophageal reflux in patients with oesophagitis: a
double-blind, placebo-controlled study. Aliment Pharmacol Ther 2002,
16:743–747.
30. Hempfling C, Neuhuber WL, Worl J: Serotonin-immunoreactive neurons
and mast cells in the mouse esophagus suggest involvement of
serotonin in both motility control and neuroimmune interactions.
Neurogastroenterol Motil 2012, 24:e67–78.
31. Clouse RE, Lustman PJ, Eckert TC, Ferney DM, Griffith LS: Low-dose
trazodone for symptomatic patients with esophageal contraction
abnormalities. A double-blind, placebo-controlled trial. Gastroenterology
1987, 92:1027–1036.
32. Broekaert D, Fischler B, Sifrim D, Janssens J, Tack J: Influence of citalopram,
a selective serotonin reuptake inhibitor, on oesophageal
hypersensitivity: a double-blind, placebo-controlled study. Aliment
Pharmacol Ther 2006, 23:365–370.
doi:10.1186/1471-244X-13-194
Cite this article as: Sanna et al.: Gastro oesophageal reflux disease
(GORD)-related symptoms and its association with mood and anxiety
disorders and psychological symptomology: a population-based study
in women. BMC Psychiatry 2013 13:194.
